We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Shenzhen YHLO Biotech Co., Ltd.

Shenzhen YHLO Biotech Co., Ltd. (YHLO) is an immunoassay solutions company that specializes in developing, manufactur... read more Featured Products: More products

Download Mobile App





YHLO Launches New SARS-CoV-2 Neutralization Antibody (NAb) Assay

By LabMedica International staff writers
Posted on 03 Mar 2021
Shenzhen YHLO Biotech Co., Ltd. More...
(Shenzhen, China) has launched its new SARS-CoV-2 NAb test kit designed to detect all antibodies that are able to inhibit the binding between S1 RBD and ACE2 in both CLIA and FIA platforms.

The test is intended to be used for the evaluation of neutralization antibodies in discharged patients, monitor neutralization antibodies in people who had COVID-19 vaccination, and the efficacy of immunotherapy. Neutralization antibody assay is essential for many vaccines and treatments for other infectious diseases, e.g. Anti-HBs assay is measuring neutralization antibody of Hepatitis B Virus. By definition, neutralization antibodies against SARS-CoV-2 can stop COVID-19 Receptor Binding Domain (RBD) from binding to Angiotensin-Converting Enzyme 2 (ACE2) receptor in human cells, which prevent SARS-CoV-2 to invade human cells.

When compared to traditional PRNT and ELISA test, YHLO’s SARS-CoV-2 NAb test kit offers the distinct advantage of being a quantitative test on the CLIA/FIA platform, which provides valuable clinical data to any studies that intend to assess either immune response or therapy efficacy in COVID-19. Additionally, the use of the CLIA/FIA method drastically improves testing capacity and efficiency, aiding the large-scale study on NAb.

Some additional advantages offered by YHLO’s SARS-CoV-2 NAb test kit include quantitative test yielding data with medical value, high throughput with short TAT (first result <30 minutes), full automation which minimizes human-induced error, cost-effectiveness and lower labor intensity, and a dynamic design that mimics the human body internal environment.




Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Immunofluorescence Analyzer
IFA System
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.